Concomitant and Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Southern Italy: Preliminary Data from a Randomized Clinical Trial
Antibiotics · 10.04.2024 · 13 (4) · 348
DOI: 10.3390/antibiotics13040348 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Antibiotics, online erschienen am 10.04.2024. Verfasst von Giuseppe Losurdo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Concomitant therapy (CT) and bismuth quadruple therapy (BQT) are recommended in geographical areas with high clarithromycin resistance for Helicobacter pylori (H. pylori) eradication. We compared CT and BQT as the first lines of treatment in a randomized controlled trial. Consecutive patients with H. pylori diagnosed by concordance of both a urea breath test and histology were recruited. For BQT, patients received 3 PyleraTM capsules q.i.d.; for CT, 1000 mg of amoxicillin b.i.d, 500 mg of clarithromycin b.i.d and 500 mg of metronidazole b.i.d. As a proton pump inhibitor, 40 mg of pantoprazole b.i.d was administered. Both regimens lasted 10 days. In total, 46 patients received CT and 38 BQT. Both groups were comparable for age (p = 0.27) and sex (p = 0.36). We did not record any drop outs; therefore, the intention to treat and per protocol rates coincided. The most common symptoms were heartburn and post-prandial fullness, which were equally present in both groups. The success rate was 95.6% for CT and 100% for BQT (p = 0.56). Side effects were recorded in 23.9% and 31.6% of patients in the CT and BQT arms, respectively (p = 0.47). The most common ones were abdominal pain (8) and diarrhea (6). In conclusion, CT and BQT are equally effective in our area with high clarithromycin resistance, southern Italy, and showed comparable safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy.
- Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS "Saverio de Bellis", 70013 Castellana Grotte, Italy.
- THD s.p.a., 42015 Correggio, Italy.
- Ph.D. Course in Organs and Tissues Transplantation and Cellular Therapies, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy.
ORCID-Profile: Giuseppe Losurdo, Francesco Russo, Grazia Galeano, Francesca Celiberto, Enzo Ierardi, Alfredo Di Leo
Zitieren
APA
Losurdo, G., Borraccino, A. V., Aloisio, A., Russo, F., Riezzo, G., Galeano, G., Pricci, M., Girardi, B., Celiberto, F., Iannone, A., Ierardi, E., & Di Leo, A. (2024). Concomitant and Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Southern Italy: Preliminary Data from a Randomized Clinical Trial. Antibiotics, 13(4), 348. https://doi.org/10.3390/antibiotics13040348
Vancouver
Losurdo G, Borraccino AV, Aloisio A, Russo F, Riezzo G, Galeano G, et al. Concomitant and Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Southern Italy: Preliminary Data from a Randomized Clinical Trial. Antibiotics. 2024;13(4):348. doi:10.3390/antibiotics13040348
BibTeX
@article{Losurdo2024,
author = {Losurdo, Giuseppe and Borraccino, Antonia Valeria and Aloisio, Adriana and Russo, Francesco and Riezzo, Giuseppe and Galeano, Grazia and Pricci, Maria and Girardi, Bruna and Celiberto, Francesca and Iannone, Andrea and Ierardi, Enzo and Di Leo, Alfredo},
title = {Concomitant and Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Southern Italy: Preliminary Data from a Randomized Clinical Trial},
journal = {Antibiotics},
year = {2024},
volume = {13},
number = {4},
pages = {348},
doi = {10.3390/antibiotics13040348}
}
EUVIMED